Degenerative disc disease (DDD) is characterized by progressive intervertebral disc (IVD) inflammation that ultimately causes lower back pain (LBP). In the present investigation, the rat needle punctured IVD degeneration (IVDD) model was established under a fluoroscopically guided system, followed by human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) transplantation. Quantitative real-time polymerase chain reaction (qPCR) was performed to quantify the pain and inflammatory molecular markers, including C-JUN, C-FOS, serine /threonine protein kinase (AKT), osteoprotegerin (OPG), receptor activator of nuclear factor ? B (RANK), toll-like receptor 4 (TLR4) and interleukin 1 beta (IL1-ß). Radiographic imaging and histological analyses showed significant IVDD after two weeks of injury, and the hUC-MSC group exhibited the restored nucleus pulposus (NP) region and the significant presence of proteoglycans in contrast to the degenerated group. When compared to healthy IVDs, the molecular expression of pain and inflammatory genes was significantly increased on days 2 and 5, resulting in an immunomodulatory response and a marked IVDD. Conversely, the hUC-MSC group at 2 and 5 days showed significantly downregulated expression of C-JUN (***p = 0.001 and **p = 0.01 respectively), C-FOS (**p = 0.01), OPG (***p = 0.001 on day 2), RANK (**p = 0.01), TLR4 (***p = 0.001 on day 5) and IL1-ß (**p = 0.01 on day 2), compared to the IVDD group. MSCs transplanted group also showed significant upregulation on days 2 and 5 in the anti-inflammatory marker AKT (***p = 0.001 and **p = 0.01, respectively) expression. Moreover, the hUC-MSCs-treated group indicated significant NP hydration. The preclinical transplantation of hUC-MSCs can potentially reduce the pain and inflammation caused by disc degeneration. Therefore, the therapy can ideally deal with all the manifestations that occur due to such debilitating DDD.